Review





Similar Products

mouse ova sigg elisa kit  (Wuhan Fine Biotech)
93
Wuhan Fine Biotech mouse ova sigg elisa kit
Antitumor mechanism of <t>Len/OVA/yMSNs.</t> (A) Immunohistochemical images and quantitative analysis of CD31 expression in tumors after 14 days of treatment ( n = 3). (B) Schematic of TME after treatment, in which prime M2 macrophages could revert to M1 phenotype, OVA-specific CD8+ T cells could infiltrate tumors, and antitumoral cytokines could be secreted. (C–E) Immunofluorescence images of the tumors showing the polarization of M1 macrophages (C1), M2 macrophages (D1) and the infiltration of OVA-specific CD8 + T cells (E1) in different treatment groups; scale bar = 100 μm. FCManalysis of the tumors showing the ratio of M1 macrophages (C2), M2 macrophages (D2) and infiltration of OVA-specific CD8 + T cells (E2) in different treatment groups ( n = 3). (F, G) <t>ELISA</t> analysis of Len/OVA/yMSN-induced secretion of proinflammatory cytokines including TNF- α and INF- γ in tumors ( n = 3). Groups 1–7 respectively represent 1-saline, 2-Len, 3-Len/yMSNs, 4-Len/OVA/MSNs, 5-Len/OVA/yMSNs, 6-OVA/yMSNs, and 7-Len/yMSNs + OVA/yMSNs. All of the data are presented as the mean ± SD. ∗∗∗ P < 0.001. ns , not significance.
Mouse Ova Sigg Elisa Kit, supplied by Wuhan Fine Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/em1607/pmc09764130-142-24-29?v=Wuhan+Fine+Biotech
Average 93 stars, based on 1 article reviews
mouse ova sigg elisa kit - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


Antitumor mechanism of Len/OVA/yMSNs. (A) Immunohistochemical images and quantitative analysis of CD31 expression in tumors after 14 days of treatment ( n = 3). (B) Schematic of TME after treatment, in which prime M2 macrophages could revert to M1 phenotype, OVA-specific CD8+ T cells could infiltrate tumors, and antitumoral cytokines could be secreted. (C–E) Immunofluorescence images of the tumors showing the polarization of M1 macrophages (C1), M2 macrophages (D1) and the infiltration of OVA-specific CD8 + T cells (E1) in different treatment groups; scale bar = 100 μm. FCManalysis of the tumors showing the ratio of M1 macrophages (C2), M2 macrophages (D2) and infiltration of OVA-specific CD8 + T cells (E2) in different treatment groups ( n = 3). (F, G) ELISA analysis of Len/OVA/yMSN-induced secretion of proinflammatory cytokines including TNF- α and INF- γ in tumors ( n = 3). Groups 1–7 respectively represent 1-saline, 2-Len, 3-Len/yMSNs, 4-Len/OVA/MSNs, 5-Len/OVA/yMSNs, 6-OVA/yMSNs, and 7-Len/yMSNs + OVA/yMSNs. All of the data are presented as the mean ± SD. ∗∗∗ P < 0.001. ns , not significance.

Journal: Acta Pharmaceutica Sinica. B

Article Title: Immune-awakenin g Saccharomyces -inspired nanocarrier for oral target delivery to lymph and tumors

doi: 10.1016/j.apsb.2022.04.018

Figure Lengend Snippet: Antitumor mechanism of Len/OVA/yMSNs. (A) Immunohistochemical images and quantitative analysis of CD31 expression in tumors after 14 days of treatment ( n = 3). (B) Schematic of TME after treatment, in which prime M2 macrophages could revert to M1 phenotype, OVA-specific CD8+ T cells could infiltrate tumors, and antitumoral cytokines could be secreted. (C–E) Immunofluorescence images of the tumors showing the polarization of M1 macrophages (C1), M2 macrophages (D1) and the infiltration of OVA-specific CD8 + T cells (E1) in different treatment groups; scale bar = 100 μm. FCManalysis of the tumors showing the ratio of M1 macrophages (C2), M2 macrophages (D2) and infiltration of OVA-specific CD8 + T cells (E2) in different treatment groups ( n = 3). (F, G) ELISA analysis of Len/OVA/yMSN-induced secretion of proinflammatory cytokines including TNF- α and INF- γ in tumors ( n = 3). Groups 1–7 respectively represent 1-saline, 2-Len, 3-Len/yMSNs, 4-Len/OVA/MSNs, 5-Len/OVA/yMSNs, 6-OVA/yMSNs, and 7-Len/yMSNs + OVA/yMSNs. All of the data are presented as the mean ± SD. ∗∗∗ P < 0.001. ns , not significance.

Article Snippet: To evaluate the serum antibody level, blood samples were collected on Days 14, 21, 28, and 35, and anti-OVA IgG levels were determined by Mouse OVA sIgG ELISA Kit (Wuhan Fine Biotech Co., Ltd.) analysis.

Techniques: Immunohistochemical staining, Expressing, Immunofluorescence, Enzyme-linked Immunosorbent Assay